[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[Novartis AG](/topic/$novnsw)

### Sentiment: XX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$novnsw/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$novnsw/time-series/sentiment.tsv)  
**Current Value**: XX%  
**Daily Average**: XX%  
**1 Week**: XX% -X%  
**1 Month**: XX% +11%  
**6 Months**: XX% +8%  
**1 Year**: XX% +15%  
**1-Year High**: XX% on 2024-11-16  
**1-Year Low**: XX% on 2025-08-26  

**Most Supportive Themes**
- **Kesimpta Benefits:** (35%) Positive data supporting the benefits of Kesimpta in relapsing multiple sclerosis (RMS) is being shared across multiple social networks.
- **Novartis's Innovation and Investment:** (20%) Mentions of Novartis's investments in R&D and acquisitions, such as Regulus Therapeutics, are generating positive sentiment.
- **Access to Medicines:** (15%) Positive sentiment around Novartis's efforts to provide access to medicines, particularly in collaboration with organizations like the UICC.
  
**Most Critical Themes**
- **US Price Cuts:** (10%)  Discussions around potential price cuts in the US market, driven by CEO comments and potential tariff impacts, are generating some critical sentiment.
- **Patent Revocation:** (5%)  The revocation of Novartis's patent for Vymada in India is a critical point.
  
Network engagement breakdown:  
| Network | Positive | %  | Neutral | %  | Negative | %  |
| ------- | -------- | -  | ------- | -  | -------- | -  |
| News    | X        | X% | XX      | X% |          |    |
| Reddit  | XX       | X% | XXX     | X% | XXX      | X% |
| TikTok  | XX       | X% | XXX     | X% | XXX      | X% |
| X       | XXX      | X% | XXX     | X% | XXX      | X% |
| YouTube | XX       | X% | XXX     | X% | XXX      | X% |
|         |          |    |         |    |          |    |
| Total   | XXXXX    | X% | XXXXX   | X% | XXX      | X% |